Skip to Content

Moderna Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Moderna Earnings: High-Level Long-Term Guidance Fits Our View; Maintaining $227 Valuation

Moderna reported third-quarter results that were weaker than we had anticipated, largely due to significant manufacturing resizing expenses to allow the firm to adjust to the endemic phase of COVID-19 but retain more flexibility in the future.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRNA so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center